CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress. Financially, the company achieved record revenue, driven by the strong performance of its...
CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress. Financially, the company achieved record revenue, driven by the strong performance of its...
CHENGDU, China, 15. Juni 2025 /PRNewswire/ -- Am 12. Juni hat Keymed Biosciences Inc. (HKEX: 02162) gab bekannt, dass Prof. Jun Shis Forschungsteam vom Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institut für Hämatologie, Chinesische Akademie...
CHENGDU, China, 15. Juni 2025 /PRNewswire/ -- Am 12. Juni hat Keymed Biosciences Inc. (HKEX: 02162) gab bekannt, dass Prof. Jun Shis Forschungsteam vom Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institut für Hämatologie, Chinesische Akademie...
